H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge

J Virol. 2014 Feb;88(4):2340-3. doi: 10.1128/JVI.03183-13. Epub 2013 Dec 4.

Abstract

The recent outbreak of H7N9 influenza virus infections in humans in China has raised concerns about the pandemic potential of this strain. Here, we test the efficacy of H3 stalk-based chimeric hemagglutinin universal influenza virus vaccine constructs to protect against H7N9 challenge in mice. Chimeric hemagglutinin constructs protected from viral challenge in the context of different administration routes as well as with a generic oil-in-water adjuvant similar to formulations licensed for use in humans.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adjuvants, Immunologic
  • Animals
  • Hemagglutinin Glycoproteins, Influenza Virus / genetics
  • Influenza A Virus, H7N9 Subtype*
  • Influenza Vaccines / immunology*
  • Mice
  • Orthomyxoviridae Infections / immunology
  • Orthomyxoviridae Infections / prevention & control*
  • Recombinant Fusion Proteins / genetics

Substances

  • Adjuvants, Immunologic
  • Hemagglutinin Glycoproteins, Influenza Virus
  • Influenza Vaccines
  • Recombinant Fusion Proteins